awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34363435-58CF63B3-8852-4CE5-B871-2FF0A4030CAF
Q34363435-58CF63B3-8852-4CE5-B871-2FF0A4030CAF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34363435-58CF63B3-8852-4CE5-B871-2FF0A4030CAF
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
P2860
Q34363435-58CF63B3-8852-4CE5-B871-2FF0A4030CAF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34363435-58CF63B3-8852-4CE5-B871-2FF0A4030CAF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7aa574e1ebecc5b4d63efa987f6f4b6997bd03d3
P2860
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.